Choosing a Gliptin
Year: 2011
Type: article
Abstract: The treatment of type 2 diabetes mellitus (T2DM) has included the use of metformin and sulfonylurea (SU) as first-line anti-diabetic therapies world over since years. This remains, despite the knowledge that the combination results in a progressive decline in [beta]-cell function and by 3 years up to 50% of diabetic patients can require an additional pharmacological agent to maintain the glycosylated hemoglobin (HbA1c) <7.0% (UKPDS). Gliptins represent a novel class of agents that improve beta cell health and suppress glucagon, resulting in improved post-prandial and fasting hyperglycemia. They function by augmenting the incretin system (GLP-1 and GIP) preventing their metabolism by dipeptidyl peptidase-4 (DPP-4). Not only are they efficacious but also safe (weight neutral) and do not cause significant hypoglycemia, making it a unique class of drugs. This review focuses on gliptins (sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin) discussing pharmacokinetics, pharmacodynamics, efficacy, and safety.
Authors: Vishal Gupta, Sanjay Kalra
Institutions: Jaslok Hospital, Bharti Hospital
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: DPP-4 inhibitors, type 2 diabetes, sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, incretin system, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, beta-cell function, glucagon suppression, pharmacokinetics, pharmacodynamics, drug safety and efficacy, metformin, sulfonylureas
Open Access status: diamond
OpenAlex ID: W2064443246
